

Olivier Benveniste

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2953858/publications.pdf>

Version: 2024-02-01

162
papers

9,534
citations

31902

53
h-index

45213

90
g-index

173
all docs

173
docs citations

173
times ranked

7547
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors. <i>Human Gene Therapy</i> , 2010, 21, 704-712.	1.4	776
2	Long-term observational study of sporadic inclusion body myositis. <i>Brain</i> , 2011, 134, 3176-3184.	3.7	319
3	Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies. <i>JAMA Neurology</i> , 2018, 75, 1528.	4.5	301
4	Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. <i>Neurology</i> , 2018, 91, e985-e994.	1.5	247
5	Anti-HMGCR Autoantibodies in European Patients With Autoimmune Necrotizing Myopathies. <i>Medicine (United States)</i> , 2014, 93, 150-157.	0.4	235
6	Hierarchical cluster and survival analyses of antisynthetase syndrome: Phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. <i>Autoimmunity Reviews</i> , 2012, 12, 210-217.	2.5	233
7	High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. <i>Brain</i> , 2016, 139, 2131-2135.	3.7	202
8	The EuroMyositis registry: an international collaborative tool to facilitate myositis research. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 30-39.	0.5	183
9	JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. <i>Brain</i> , 2018, 141, 1609-1621.	3.7	169
10	Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. <i>Arthritis and Rheumatism</i> , 2011, 63, 1961-1971.	6.7	168
11	A 10 Patient Case Report on the Impact of Plasmapheresis Upon Neutralizing Factors Against Adeno-associated Virus (AAV) Types 1, 2, 6, and 8. <i>Molecular Therapy</i> , 2011, 19, 2084-2091.	3.7	163
12	239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018. <i>Neuromuscular Disorders</i> , 2020, 30, 70-92.	0.3	148
13	Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 2001-2011.	6.7	147
14	Different phenotypes in dermatomyositis associated with anti-MDA5 antibody. <i>Neurology</i> , 2020, 95, e70-e78.	1.5	142
15	Immune Checkpoint Inhibitor-Associated Myositis. <i>Circulation</i> , 2018, 138, 743-745.	1.6	139
16	Phase I Study of Dystrophin Plasmid-Based Gene Therapy in Duchenne/Becker Muscular Dystrophy. <i>Human Gene Therapy</i> , 2004, 15, 1065-1076.	1.4	134
17	Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis. <i>Brain</i> , 2015, 138, 2485-2492.	3.7	134
18	Necrosis in anti-SRP and anti-HMGCR myopathies. <i>Neurology</i> , 2018, 90, e507-e517.	1.5	132

#	ARTICLE	IF	CITATIONS
19	Immune-mediated necrotizing myopathy: clinical features and pathogenesis. <i>Nature Reviews Rheumatology</i> , 2020, 16, 689-701.	3.5	131
20	Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1558-1566.	0.5	127
21	Mechanisms Involved in the Low-Level Regeneration of CD4+Cells in HIV-1 Infected Patients Receiving Highly Active Antiretroviral Therapy Who Have Prolonged Undetectable Plasma Viral Loads. <i>Journal of Infectious Diseases</i> , 2005, 191, 1670-1679.	1.9	115
22	Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken. <i>Acta Neuropathologica</i> , 2015, 129, 611-624.	3.9	112
23	Pathogenic role of anti-3-hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: Myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies. <i>Annals of Neurology</i> , 2017, 81, 538-548.	2.8	112
24	Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival. <i>European Respiratory Journal</i> , 2013, 42, 1271-1282.	3.1	108
25	Infectious Complications in Polymyositis and Dermatomyositis: A Series of 279 Patients. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 48-60.	1.6	107
26	Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study. <i>Autoimmunity Reviews</i> , 2016, 15, 983-993.	2.5	105
27	<i>In vivo</i> pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 131-139.	0.5	97
28	Advances in serological diagnostics of inflammatory myopathies. <i>Current Opinion in Neurology</i> , 2016, 29, 662-673.	1.8	96
29	<i>Myasthenia Gravis Seronegative for Acetylcholine Receptor Antibodies</i> . <i>Annals of the New York Academy of Sciences</i> , 2008, 1132, 84-92.	1.8	93
30	Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. <i>Lancet Neurology</i> , The, 2019, 18, 834-844.	4.9	91
31	Nuclear actin aggregation is a hallmark of anti-synthetase syndrome-induced dysimmune myopathy. <i>Neurology</i> , 2015, 84, 1346-1354.	1.5	90
32	Severe Perturbations of the Blood T Cell Repertoire in Polymyositis, But Not Dermatomyositis Patients. <i>Journal of Immunology</i> , 2001, 167, 3521-3529.	0.4	87
33	Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). <i>Neuromuscular Disorders</i> , 2006, 16, 334-336.	0.3	84
34	Efficacy of Rituximab in Refractory Inflammatory Myopathies Associated with Anti- Synthetase Auto-Antibodies: An Open-Label, Phase II Trial. <i>PLoS ONE</i> , 2015, 10, e0133702.	1.1	84
35	Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 996-1002.	0.5	81
36	Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. <i>Autoimmunity Reviews</i> , 2020, 19, 102586.	2.5	80

#	ARTICLE	IF	CITATIONS
37	A phase I trial of adeno-associated virus serotype 1- β -sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C. <i>Brain</i> , 2012, 135, 483-492.	3.7	78
38	Dermatomyositis With or Without Anti-Melanoma Differentiation-Associated Gene 5 Antibodies. <i>American Journal of Pathology</i> , 2016, 186, 691-700.	1.9	78
39	IFN- γ -induced reactive oxygen species and mitochondrial damage contribute to muscle impairment and inflammation maintenance in dermatomyositis. <i>Acta Neuropathologica</i> , 2017, 134, 655-666.	3.9	78
40	Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation. <i>Drug Safety</i> , 2019, 42, 813-825.	1.4	78
41	Role of Regulatory T Cells in a New Mouse Model of Experimental Autoimmune Myositis. <i>American Journal of Pathology</i> , 2009, 174, 989-998.	1.9	74
42	Acquired necrotizing myopathies. <i>Current Opinion in Neurology</i> , 2013, 26, 554-560.	1.8	68
43	Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy. <i>Acta Neuropathologica Communications</i> , 2014, 2, 154.	2.4	68
44	Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance. <i>Journal of Autoimmunity</i> , 2017, 79, 84-90.	3.0	67
45	Anti-HMGBR myopathy may resemble limb-girdle muscular dystrophy. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2019, 6, e523.	3.1	66
46	Shared blood and muscle CD8+ T-cell expansions in inclusion body myositis. <i>Brain</i> , 2006, 129, 986-995.	3.7	65
47	Th1 Response and Systemic Treg Deficiency in Inclusion Body Myositis. <i>PLoS ONE</i> , 2014, 9, e88788.	1.1	65
48	Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies. <i>JCI Insight</i> , 2020, 5, .	2.3	65
49	Sarcoidosis and interferon therapy: report of five cases and review of the literature. <i>European Journal of Internal Medicine</i> , 2003, 14, 237-243.	1.0	58
50	Exploring necrotizing autoimmune myopathies with a novel immunoassay for anti-3-hydroxy-3-methyl-glutaryl-CoA reductase autoantibodies. <i>Arthritis Research and Therapy</i> , 2014, 16, R39.	1.6	57
51	MuSK antibody positive myasthenia gravis plasma modifies MURF-1 expression in C2C12 cultures and mouse muscle in vivo. <i>Journal of Neuroimmunology</i> , 2005, 170, 41-48.	1.1	55
52	Development of a multivariate prediction model of intensive care unit transfer or death: A French prospective cohort study of hospitalized COVID-19 patients. <i>PLoS ONE</i> , 2020, 15, e0240711.	1.1	54
53	Myositis or dystrophy? Traps and pitfalls. <i>Presse Medicale</i> , 2011, 40, e249-e255.	0.8	53
54	Differential roles of hypoxia and innate immunity in juvenile and adult dermatomyositis. <i>Acta Neuropathologica Communications</i> , 2016, 4, 45.	2.4	52

#	ARTICLE	IF	CITATIONS
55	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2017, 69, 898-910.	2.9	52
56	IgG reactivity with a 100-kDa tissue and endothelial cell antigen identified as topoisomerase 1 distinguishes between limited and diffuse systemic sclerosis patients. <i>Clinical Immunology</i> , 2004, 111, 241-251.	1.4	49
57	Antisynthetase Syndrome with Anti-Jo1 Antibodies in 48 Patients: Pulmonary Involvement Predicts Disease-modifying Antirheumatic Drug Use. <i>Journal of Rheumatology</i> , 2012, 39, 1835-1839.	1.0	48
58	Biomarkers in Inflammatory Myopathies—An Expanded Definition. <i>Frontiers in Neurology</i> , 2019, 10, 554.	1.1	48
59	Mortality and Causes of Death in Patients with Sporadic Inclusion Body Myositis: Survey Study Based on the Clinical Experience of Specialists in Australia, Europe and the USA. <i>Journal of Neuromuscular Diseases</i> , 2016, 3, 67-75.	1.1	44
60	Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy. <i>Autoimmunity Reviews</i> , 2019, 18, 223-230.	2.5	44
61	The role of interferons type I, II and III in myositis: A review. <i>Brain Pathology</i> , 2021, 31, e12955.	2.1	44
62	Quadriceps strength is a sensitive marker of disease progression in sporadic inclusion body myositis. <i>Neuromuscular Disorders</i> , 2012, 22, 980-986.	0.3	43
63	Non-invasive differentiation of idiopathic inflammatory myopathy with cardiac involvement from acute viral myocarditis using cardiovascular magnetic resonance imaging T1 and T2 mapping. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2018, 20, 11.	1.6	42
64	PD1 pathway in immune-mediated myopathies. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e558.	3.1	42
65	Sequestosome-1 (p62) expression reveals chaperone-assisted selective autophagy in immune-mediated necrotizing myopathies. <i>Brain Pathology</i> , 2020, 30, 261-271.	2.1	42
66	Analysis of Autoantibodies to 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Using Different Technologies. <i>Journal of Immunology Research</i> , 2014, 2014, 1-8.	0.9	41
67	Four-year longitudinal study of clinical and functional endpoints in sporadic inclusion body myositis: Implications for therapeutic trials. <i>Neuromuscular Disorders</i> , 2014, 24, 604-610.	0.3	41
68	Immune Array Analysis in Sporadic Inclusion Body Myositis Reveals HLA-DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum. <i>Arthritis and Rheumatology</i> , 2017, 69, 1090-1099.	2.9	41
69	Resistant myasthenia gravis and rituximab: A monocentric retrospective study of 28 patients. <i>Neuromuscular Disorders</i> , 2017, 27, 251-258.	0.3	41
70	Paradoxical intracranial cryptococcoma in a human immunodeficiency virus-infected man being treated with combination antiretroviral therapy. <i>American Journal of Medicine</i> , 2002, 113, 155-157.	0.6	40
71	Sporadic late-onset nemaline myopathy with MGUS. <i>Neurology</i> , 2014, 83, 2133-2139.	1.5	40
72	Cytokine mRNA Expression in Mononuclear Cells from Different Tissues during Acute SIVmac251 Infection of Macaques. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 1263-1272.	0.5	39

#	ARTICLE	IF	CITATIONS
73	Value of biomarkers for predicting immunoglobulin A vasculitis nephritis outcome in an adult prospective cohort. <i>Nephrology Dialysis Transplantation</i> , 2017, 33, 1579-1590.	0.4	37
74	Rituximab in the Treatment of Refractory Anti-HMGR Immune-mediated Necrotizing Myopathy. <i>Journal of Rheumatology</i> , 2019, 46, 623-627.	1.0	36
75	The immunoproteasomes are key to regulate myokines and MHC class I expression in idiopathic inflammatory myopathies. <i>Journal of Autoimmunity</i> , 2016, 75, 118-129.	3.0	34
76	The IgG2 Isotype of Anti-Transcription Intermediary Factor 1 ^β Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1360-1370.	2.9	33
77	Expression of myogenic regulatory factors and myo-endothelial remodeling in sporadic inclusion body myositis. <i>Neuromuscular Disorders</i> , 2013, 23, 75-83.	0.3	32
78	Sirrolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial. <i>Lancet Rheumatology</i> , The, 2021, 3, e40-e48.	2.2	32
79	Cytokine mRNA levels in unmanipulated (ex vivo) and in vitro stimulated monkey PBMCs using a semi-quantitative RT-PCR and high sensitivity fluorescence-based detection strategy. <i>Cytokine</i> , 1996, 8, 32-41.	1.4	31
80	Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis. <i>Journal of Neuromuscular Diseases</i> , 2018, 5, 241-249.	1.1	31
81	Interleukin 1 ^β , Interleukin 6, Tumor Necrosis Factor α , and Interleukin 10 Responses in Peripheral Blood Mononuclear Cells of Cynomolgus Macaques during Acute Infection with SIVmac251. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 241-250.	0.5	30
82	Sporadic late-onset nemaline myopathy with monoclonal gammopathy of undetermined significance. <i>Current Opinion in Neurology</i> , 2017, 30, 457-463.	1.8	30
83	Muscle Shear Wave Elastography in Inclusion Body Myositis: Feasibility, Reliability and Relationships with Muscle Impairments. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 1423-1432.	0.7	30
84	Successful Percutaneous Dihydrotestosterone Treatment of Gynecomastia Occurring during Highly Active Antiretroviral Therapy: Four Cases and a Review of the Literature. <i>Clinical Infectious Diseases</i> , 2001, 33, 891-893.	2.9	28
85	Severe axial and pelvifemoral muscle damage in immune-mediated necrotizing myopathy evaluated by whole-body MRI. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1437-1440.	1.6	28
86	Beneficial Role of Rapamycin in Experimental Autoimmune Myositis. <i>PLoS ONE</i> , 2013, 8, e74450.	1.1	27
87	MRI and muscle imaging for idiopathic inflammatory myopathies. <i>Brain Pathology</i> , 2021, 31, e12954.	2.1	27
88	Involvement of NK Cells and NKp30 Pathway in Antisynthetase Syndrome. <i>Journal of Immunology</i> , 2016, 197, 1621-1630.	0.4	26
89	Antiphospholipid antibodies and thrombotic events in COVID-19 patients hospitalized in medicine ward. <i>Autoimmunity Reviews</i> , 2021, 20, 102729.	2.5	26
90	Analysis of cell surface and intranuclear markers on non-stimulated human PBMC using mass cytometry. <i>PLoS ONE</i> , 2018, 13, e0194593.	1.1	26

#	ARTICLE	IF	CITATIONS
91	Two Episodes of Acute Renal Failure, Rhabdomyolysis, and Severe Hepatitis in an AIDS Patient Successively Treated with Ritonavir and Indinavir. <i>Clinical Infectious Diseases</i> , 1999, 28, 1180-1181.	2.9	23
92	Endocarditis Due to <i>Neisseria bacilliformis</i> in a Patient with a Bicuspid Aortic Valve. <i>Journal of Clinical Microbiology</i> , 2009, 47, 1973-1975.	1.8	22
93	CD8+T-bet+ cells as a predominant biomarker for inclusion body myositis. <i>Autoimmunity Reviews</i> , 2019, 18, 325-333.	2.5	21
94	213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18-20 September 2015. <i>Neuromuscular Disorders</i> , 2016, 26, 523-534.	0.3	19
95	Architectural B-cell organization in skeletal muscle identifies subtypes of dermatomyositis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e451.	3.1	19
96	Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 127.	1.2	19
97	Comparison of MR T1 and T2 mapping parameters to characterize myocardial and skeletal muscle involvement in systemic idiopathic inflammatory myopathy (IIM). <i>European Radiology</i> , 2019, 29, 5139-5147.	2.3	19
98	Global versus individual muscle segmentation to assess quantitative MRI-based fat fraction changes in neuromuscular diseases. <i>European Radiology</i> , 2021, 31, 4264-4276.	2.3	19
99	Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis. <i>Acta Neuropathologica</i> , 2022, 144, 353-372.	3.9	19
100	Local Texture Anisotropy as an Estimate of Muscle Quality in Ultrasound Imaging. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 1133-1140.	0.7	18
101	Neurological diseases of unknown etiology: Brain-biopsy diagnostic yields and safety. <i>European Journal of Internal Medicine</i> , 2020, 80, 78-85.	1.0	18
102	Rituximab and Cyclophosphamide in Antisynthetase Syndrome-related Interstitial Lung Disease: An Observational Retrospective Study. <i>Journal of Rheumatology</i> , 2020, 47, 1678-1686.	1.0	18
103	Systematic retrospective study of 64 patients with anti-Mi2 dermatomyositis: A classic skin rash with a necrotizing myositis and high risk of malignancy. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1759-1763.	0.6	18
104	Lack of Interleukin 10 Expression in Monocyte-Derived Macrophages in Response to In Vitro Infection by HIV Type 1 Isolates. <i>AIDS Research and Human Retroviruses</i> , 1997, 13, 961-966.	0.5	17
105	HTLV-1-associated inflammatory myopathies: Low proviral load and moderate inflammation in 13 patients from West Indies and West Africa. <i>Journal of Clinical Virology</i> , 2013, 57, 70-76.	1.6	17
106	Clinical and multi-omics cross-phenotyping of patients with autoimmune and autoinflammatory diseases: the observational TRANSIMMUNOM protocol. <i>BMJ Open</i> , 2018, 8, e021037.	0.8	17
107	The seasonality of Dermatomyositis associated with anti-MDA5 antibody: An argument for a respiratory viral trigger. <i>Autoimmunity Reviews</i> , 2021, 20, 102788.	2.5	17
108	Physical activity monitoring: A promising outcome measure in idiopathic inflammatory myopathies. <i>Neurology</i> , 2017, 89, 101-103.	1.5	16

#	ARTICLE	IF	CITATIONS
109	Peculiar clinicopathological features of immune-mediated necrotizing myopathies. <i>Current Opinion in Rheumatology</i> , 2018, 30, 655-663.	2.0	16
110	Autoantibody testing in idiopathic inflammatory myopathies. <i>Practical Neurology</i> , 2019, 19, 284-294.	0.5	16
111	Rare myopathy associated to MGUS, causing heart failure and responding to chemotherapy. <i>Annals of Hematology</i> , 2017, 96, 695-696.	0.8	15
112	Anti-mitochondrial antibodies are not a hallmark of severity in idiopathic inflammatory myopathies. <i>Joint Bone Spine</i> , 2018, 85, 375-376.	0.8	14
113	Anti-RNP antibodies delineate a subgroup of myositis: A systematic retrospective study on 46 patients. <i>Autoimmunity Reviews</i> , 2020, 19, 102465.	2.5	14
114	Secondary hypersomnia as an initial manifestation of neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101869.	0.9	14
115	Relationship between change in physical activity and in clinical status in patients with idiopathic inflammatory myopathy: A prospective cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1140-1149.	1.6	14
116	Mass cytometry reveals an impairment of B cell homeostasis in anti-synthetase syndrome. <i>Journal of Neuroimmunology</i> , 2019, 332, 212-215.	1.1	13
117	Edematous myositis: a clinical presentation first suggesting dermatomyositis diagnosis. <i>Brain Pathology</i> , 2020, 30, 867-876.	2.1	13
118	Tumor necrosis factor- α in serum of macaques during SIV _{mac251} acute infection. <i>Journal of Medical Primatology</i> , 1995, 24, 94-100.	0.3	12
119	Inflammatory or necrotizing myopathies, myositides and other acquired myopathies, new insight in 2011. <i>Presse Medicale</i> , 2011, 40, e197-e198.	0.8	12
120	Expanding the spectrum of livedoid vasculopathy: peculiar neuromuscular manifestations. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 849-852.	1.8	12
121	Inclusion body myositis: accumulation of evidence for its autoimmune origin. <i>Brain</i> , 2019, 142, 2549-2551.	3.7	12
122	Correspondence on "Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey". <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e30-e30.	0.5	11
123	NanoString technology distinguishes anti-TIF1 ³ from anti-Mi2 ⁺ dermatomyositis patients. <i>Brain Pathology</i> , 2021, 31, e12957.	2.1	11
124	Potential Pathogenic Role of Anti-Signal Recognition Protein and Anti-3-hydroxy-3-methylglutaryl-CoA Reductase Antibodies in Immune-Mediated Necrotizing Myopathies. <i>Current Rheumatology Reports</i> , 2018, 20, 56.	2.1	10
125	Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. <i>PLoS ONE</i> , 2020, 15, e0242306.	1.1	10
126	Cornea verticillata and acroparesthesia efficiently discriminate clusters of severity in Fabry disease. <i>PLoS ONE</i> , 2020, 15, e0233460.	1.1	9

#	ARTICLE	IF	CITATIONS
127	Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. <i>Therapie</i> , 2021, 76, 285-295.	0.6	8
128	NK Cell Patterns in Idiopathic Inflammatory Myopathies with Pulmonary Affection. <i>Cells</i> , 2021, 10, 2551.	1.8	8
129	Responsiveness to Change of 5-point MRC scale, Endurance and Functional Evaluation for Assessing Myositis in Daily Clinical Practice. <i>Journal of Neuromuscular Diseases</i> , 2019, 6, 99-107.	1.1	7
130	Expanding the spectrum of HIV-associated myopathy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1296-1298.	0.9	7
131	Routine monitoring of isometric knee extension strength in patients with muscle impairments using a new portable device: cross-validation against a standard isokinetic dynamometer. <i>Physiological Measurement</i> , 2020, 41, 015003.	1.2	7
132	Endoplasmic reticulum stress and unfolded protein response activation in immune-mediated necrotizing myopathy. <i>Brain Pathology</i> , 2022, 32, .	2.1	7
133	Nef and Gag Synthetic Peptide Priming of Antibody Responses to HIV Type 1 Antigens in Mice and Primates. <i>AIDS Research and Human Retroviruses</i> , 1994, 10, 1241-1250.	0.5	6
134	Distal inflammatory myopathy: Unusual presentation of polymyositis or new entity?. <i>Neuromuscular Disorders</i> , 2008, 18, 493-500.	0.3	6
135	Lean regional muscle volume estimates using explanatory bioelectrical models in healthy subjects and patients with muscle wasting. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 39-51.	2.9	6
136	Gene therapy, an ongoing revolution. <i>Blood</i> , 2012, 119, 2973-2974.	0.6	5
137	Cytokine profile as a prognostic tool in coronavirus disease 2019. Comment on "Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome" by Quartuccio et al. <i>Joint Bone Spine</i> . 2020;87:191-193. <i>Joint Bone Spine</i> , 2021, 88, 105074.	0.8	5
138	Reply: A child with severe juvenile dermatomyositis treated with ruxolitinib. <i>Brain</i> , 2018, 141, e81-e81.	3.7	4
139	Quickly progressive amyotrophy of the thigh: An unusual cause of rapid chondrolysis of the knee. <i>Joint Bone Spine</i> , 2015, 82, 203-205.	0.8	3
140	Dermoskeletons to preserve mobility and function in inclusion body myositis. <i>Neurology</i> , 2018, 91, 760-760.	1.5	3
141	Reply: Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. <i>Brain</i> , 2019, 142, e60-e60.	3.7	3
142	Functional Consequences of Macrophage Infection by Human Immunodeficiency Virus: Bispecific Antibody Targeting of HIV-1-Infected Cells to FcγRI Expressing Effector Cells. <i>Stem Cells and Development</i> , 1995, 4, 579-585.	1.0	2
143	Interferon-γ Inhibition by Intravenous Immunoglobulin Is Independent of Modulation of the Plasmacytoid Dendritic Cell Population in the Circulation: Comment on the Article by Wiedeman et al. <i>Arthritis and Rheumatology</i> , 2014, 66, 2308-2309.	2.9	2
144	Response to: "Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteria"™ by Cavagna et al. <i>Annals of the Rheumatic Diseases</i> , 2017, 77, annrheumdis-2017-212382.	0.5	2

#	ARTICLE	IF	CITATIONS
145	Of the importance of the clinical phenotypes in the interpretation of the studies dealing with Fabry disease. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 4.	1.2	2
146	Nonsystemic vasculitic neuropathy: Presentation and long-term outcome from a French cohort of 50 patients. <i>Autoimmunity Reviews</i> , 2021, 20, 102874.	2.5	2
147	Reply: Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis. <i>Brain</i> , 2019, 142, e9-e9.	3.7	1
148	Response to: Comment on "Systematic retrospective study on 64 patients anti-Mi2 dermatomyositis: A classic skin rash with a necrotizing myositis and high risk of malignancy". <i>Journal of the American Academy of Dermatology</i> , 2020, 83, e461-e462.	0.6	1
149	Echocardiography and renin-aldosterone interplay as predictors of death in COVID-19. <i>Archives of Cardiovascular Diseases</i> , 2022, 115, 96-96.	0.7	1
150	Four cross-linked HIV Gag peptides prime the immune response to HIV proteins in mice. <i>Peptides</i> , 1994, 15, 935-943.	1.2	0
151	Autoantibodies at the Center of (sub)Classification"Issues of Detection"Reply. <i>JAMA Neurology</i> , 2019, 76, 868.	4.5	0
152	Infliximab as effective treatment for aseptic neutrophilic myositis. <i>Neurology</i> , 2019, 93, 1009-1011.	1.5	0
153	Response to: "On using machine learning algorithms to define clinically meaningful patient subgroups"™ by Pinal-Fernandez and Mammen. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e130-e130.	0.5	0
154	La myosite Å inclusions. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2018, 202, 91-103.	0.0	0
155	Title is missing!. , 2020, 15, e0233460.		0
156	Title is missing!. , 2020, 15, e0233460.		0
157	Title is missing!. , 2020, 15, e0233460.		0
158	Title is missing!. , 2020, 15, e0233460.		0
159	Title is missing!. , 2020, 15, e0240711.		0
160	Title is missing!. , 2020, 15, e0240711.		0
161	Title is missing!. , 2020, 15, e0240711.		0
162	Title is missing!. , 2020, 15, e0240711.		0